KRRO
Korro Bio, Inc.
$11.61
+0.41
(+3.66%)
Mkt Cap
115.56M
Volume
231,200
52W Range
5.204-55.89
Sector
Healthcare
Beta
2.23
EPS (TTM)
-11.68
P/E Ratio
-0.64
Revenue (TTM)
3.84M
Rev Growth (5Y)
-29.6%
EPS Growth (5Y)
N/A
Company Description
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.39M | 2.27M | 0 | 0 | 14.07M | 36.98M | 28.95M | 0 | 0 |
| Net Income | (117.26M) | (83.58M) | (81.17M) | (58.03M) | (84.69M) | (26.51M) | (18.75M) | (19.17M) | (20.24M) |
| EPS | -12.48 | -9.37 | -53.09 | -227.58 | -4.94 | -41.10 | -30.39 | -30.57 | -32.27 |
| Free Cash Flow | (79.08M) | (77.98M) | (75.12M) | (58.86M) | (36.54M) | (51.86M) | 33.15M | (17.46M) | (16.48M) |
| FCF / Share | -8.42 | -8.74 | -49.13 | -230.81 | -8.22 | -80.39 | 53.74 | -27.84 | -26.28 |
| Operating CF | (78.56M) | (60.07M) | (67.28M) | (53.65M) | (32.09M) | (45.19M) | 34.22M | (17.02M) | (14.61M) |
| Total Assets | 113.51M | 226.24M | 221.66M | 73.74M | 185.36M | 264.72M | 223.22M | 44.55M | 19.79M |
| Total Debt | 43.49M | 44.77M | 33.21M | 166.99M | 45.60M | 45.99M | 0 | 84.94M | 46.69M |
| Cash & Equiv | 21.82M | 55.64M | 166.15M | 36.94M | 79.64M | 220.34M | 200.16M | 42.19M | 17.94M |
| Book Value | 51.44M | 160.41M | 169.91M | (99.03M) | 130.82M | 192.49M | 167.36M | (48.28M) | (29.64M) |
| Return on Equity | -2.28 | -0.52 | -0.48 | N/A | -0.65 | -0.14 | -0.11 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1.29M | 1.09M | 1.46M | 2.55M | 2.27M | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.62M) | (50.04M) | (18.06M) | (25.77M) | (23.39M) | (21.20M) | (21.00M) | (21.83M) | (19.56M) | (25.43M) | (18.49M) | (17.65M) |
| EPS | -1.69 | -5.33 | -1.92 | -2.74 | -2.49 | -2.26 | -2.26 | -2.43 | -2.44 | -4.89 | -2.03 | -1.94 |
| Free Cash Flow | (16.09M) | (17.79M) | (17.35M) | (19.37M) | (24.57M) | (8.95M) | (20.97M) | (20.55M) | (27.50M) | (47.66M) | (12.02M) | (19.14M) |
| FCF / Share | -1.39 | -1.89 | -1.85 | -2.06 | -2.62 | -1.00 | -2.25 | -2.29 | -3.43 | -5.95 | -2.10 | -3.44 |
| Operating CF | (16.07M) | (17.70M) | (17.18M) | (19.23M) | (24.45M) | (7.50M) | (16.09M) | (14.59M) | (21.89M) | (39.92M) | (11.77M) | (14.71M) |
| Total Assets | 183.62M | 113.51M | 161.55M | 180.43M | 202.21M | 226.24M | 243.54M | 249.59M | 197.99M | 221.66M | 95.83M | 109.34M |
| Total Debt | 42.88M | 43.49M | 44.67M | 44.63M | 45.19M | 44.77M | 41.78M | 38.46M | 35.92M | 33.21M | 31.22M | 29.00M |
| Cash & Equiv | 61.70M | 21.82M | 25.16M | 33.61M | 64.14M | 55.64M | 63.21M | 91.15M | 138.80M | 166.15M | 46.12M | 59.33M |
| Book Value | 119.63M | 51.44M | 99.03M | 115.10M | 138.96M | 160.41M | 179.63M | 198.08M | 151.36M | 169.91M | 56.06M | 73.92M |
| Return on Equity | -0.16 | -0.97 | -0.18 | -0.22 | -0.17 | -0.13 | -0.12 | -0.11 | -0.13 | -0.15 | -0.33 | -0.24 |
KRRO News
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Korro to Participate in Upcoming Investor Conferences
What Makes Korro Bio, Inc. (KRRO) a New Buy Stock
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook
Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates